<DOC>
	<DOCNO>NCT00301145</DOCNO>
	<brief_summary>RATIONALE : Varenicline tartrate may help people quit smoke decrease symptom nicotine withdrawal . It yet know whether varenicline tartrate effective help people stop smoke give together telephone-based counseling program , Internet-based counseling program , program . PURPOSE : This randomized clinical trial study well give varenicline tartrate together telephone-based counseling program and/or Internet-based counseling program work help adult stop smoking .</brief_summary>
	<brief_title>Varenicline Tartrate With Telephone-Based Counseling and/or Internet-Based Counseling Helping Adults Stop Smoking</brief_title>
	<detailed_description>OBJECTIVES : - Determine effectiveness varenicline telephone counsel vs Internet-based counseling v telephone counsel Internet-based smoking cessation intervention adult smoker . - Determine individual group difference patient undergoing intervention . - Determine heterogeneity responsiveness regard Classification Regression Tree Analysis patient undergoing intervention . - Determine effectiveness intervention regard recruitment , implementation , barrier treatment , exposure intervention , satisfaction treatment , treatment contamination , program maintenance . - Determine cost-effectiveness intervention . OUTLINE : This randomize , open-label study . Patients randomize 1 3 intervention arm . - Arm I : Patients undergo proactive telephone-based ( PTB ) smoke cessation program . - Arm II : Patients undergo web-based ( WB ) smoke cessation program . - Arm III : Patients undergo integrate PTB/WB smoke cessation program . Beginning 1 week target quit date , patient receive oral varenicline daily 3 day twice daily 12 week . They also receive mail packet contain welcome letter , description intervention service offer , privacy notice , Free &amp; Clear Quit Kit ( comprehensive education/self-help material include health smoking substitution ) , phone call orient patient intervention randomize , access toll-free support line . All patient undergo pre-treatment assessment ( pre-quit ) 3 post-quit assessment 21 day , 12 week , 6 month original schedule quit date determine medication adherence , treatment utilization , point-prevalent smoking outcome , continuous nonsmoking . PROJECTED ACCRUAL : A total 1,200 patient accrue study .</detailed_description>
	<mesh_term>Varenicline</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Smokes 10 cigarettes/day past year AND ≥ 5 cigarettes/day within past week Planning stop smoke 46 week Member Group Health Cooperative ( GHC ) plan stay enrol next 6 month Eligible Free &amp; Clear program Enrolled COMPASS study use bupropion hydrochloride medication No prior participation GHC 's Free &amp; Clear smoking cessation program within past 6 month PATIENT CHARACTERISTICS : In good general health Sufficient verbal write English Dependable access telephone Internet Not currently drink ≥ 14 alcoholic drink per week and/or binge drink ≥ 2 time past month Not pregnant nursing No plan become pregnant No severe chronic heart disease ( e.g , myocardial infarction within past 3 month ) No severe chronic obstructive pulmonary disease ever require hospitalization oxygen treatment No diagnosis treatment psychotic disorder ( e.g. , schizophrenia , bipolar disorder , mania ) Not certain kidney problem PRIOR CONCURRENT THERAPY : See Disease Characteristics No concurrent use medication contraindicate bupropion hydrochloride know low seizure threshold ( e.g. , antidepressant , antipsychotic , monamine oxidase inhibitor , protease inhibitor ) No concurrent use recreational street drug No concurrent use bupropion hydrochloride nicotine replacement therapy No concurrent cimetidine , metformin , phenformin , pindolol , procainamide Not dialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>